Investing.com - Financial Markets Worldwide

Sichuan Biokin Pharmaceutical Co (688506)

Shanghai
Currency in CNY
312.56
+16.31(+5.51%)
Closed·

688506 Financial Summary

Key Ratios

P/E Ratio32.16
Price/Book30.7
Debt / Equity53.23%
Return on Equity183.64%
Dividend Yield0.00%
EBITDA3.75B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2011
31/12
2012
31/12
2013
31/12
2014
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1,012.71796.73703.28561.875,822.72
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa810.69593.34465.58319.615,538.98
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-22.85-159.52-329.83-785.63,686.33
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa37.9-99.99-282.38-780.53,707.5
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa1,041.99951.461,991.431,425.17,137.36
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa532.45471.32737.21,053.831,979.95
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa452.08331.85933.89151.873,885.92
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa65.39-135.4-145.1-3962,692.1
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa78.46-135.03-258.65-615.354,058.67
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-210156.15-34.55-81.88-2,565.44
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-64.7688.661,139.4190.841,273.89
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-198.31109.01846.47-6092,816.31
* In Millions of CNY (except for per share items)

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 307.04
(-1.77% Downside)

Earnings

Latest Release
Mar 28, 2025
EPS / Forecast
-0.89 / --
Revenue / Forecast
160.16M / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Sichuan Biokin Pharmaceutical's earnings for the latest quarter?

The Sichuan Biokin Pharmaceutical EPS (TTM) is 9.25. Sichuan Biokin Pharmaceutical reported sales of 160.16, net income of -357.86, and EPS of -0.89 for the latest quarter.

What was Sichuan Biokin Pharmaceutical's net income for the latest quarter?

Sichuan Biokin Pharmaceutical's net income for the latest quarter was -357.86.

How did Sichuan Biokin Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 109.83 in the previous quarter to 160.16 in the latest quarter, and net income moved from -600.97 to -357.86 compared to the previous quarter.

What is Sichuan Biokin Pharmaceutical's net profit margin on a TTM basis?

Sichuan Biokin Pharmaceutical's trailing twelve months (TTM) net profit margin is 63.67%.

How does Sichuan Biokin Pharmaceutical's debt to equity ratio compare to industry standards?

Sichuan Biokin Pharmaceutical's total debt-to-equity ratio is 53.23%.

What is Sichuan Biokin Pharmaceutical's return on investment on a TTM basis?

Sichuan Biokin Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 183.64%.

Did Sichuan Biokin Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Sichuan Biokin Pharmaceutical's net change in cash was -1,714.58 million.

What were Sichuan Biokin Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Sichuan Biokin Pharmaceutical reported total assets of 7,137.36 million and total liabilities of 1,979.95 million.

How has Sichuan Biokin Pharmaceutical's total revenue grown this year?

Sichuan Biokin Pharmaceutical's total revenue was 109.83 in the previous quarter and 160.16 in the latest quarter.

What is Sichuan Biokin Pharmaceutical's gross margin on a TTM basis?

Sichuan Biokin Pharmaceutical's trailing twelve months (TTM) gross margin is 95.13%.

What was Sichuan Biokin Pharmaceutical's revenue per share for the latest quarter?

Sichuan Biokin Pharmaceutical's revenue per share for the latest quarter was 6.96.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.